Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Psoriasis-Two Centuries after Its Discovery: Pathogenesis and Treatment
share announcement

Psoriasis-Two Centuries after Its Discovery: Pathogenesis and Treatment

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 4079

Special Issue Editors

Dr. Anna Campanati

E-Mail Website
Guest Editor
Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy
Interests: skin immune-mediated skin diseases; psoriasis; suppurative hidradenitis; chronic urticaria; atopic dermatitis; adnexal diseases; melanoma and non-melanoma skin cancer; scleroderma
Special Issues, Collections and Topics in MDPI journals
Dr. Giulia Radi

E-Mail Website
Guest Editor
Dermatological Clinic, Polytechnic Marche University, 60200 Ancona, Italy
Interests: skin immune-mediated skin diseases; psoriasis; suppurative hidradenitis; chronic urticaria; atopic dermatitis; adnexal diseases; auto-inflammatory dermatoses; acne; contact dermatitis; scleroderma
Dr. Emanuela Martina

E-Mail Website
Guest Editor
Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy
Interests: skin immune-mediated skin diseases; psoriasis; suppurative hidradenitis; chronic urticaria; atopic dermatitis; adnexal diseases; auto-inflammatory dermatoses; acne; contact dermatitis; scleroderma
Dr. Federico Diotallevi

E-Mail Website
Guest Editor
Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60100 Ancona, Italy
Interests: skin immune-mediated skin diseases; psoriasis; suppurative hidradenitis; chronic urticaria; atopic dermatitis; adnexal diseases; auto-inflammatory dermatoses; acne; contact dermatitis; scleroderma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Psoriasis is an inflammatory and immune-mediated skin disease first discovered by the medical community in the early 19th century. Researchers have learned much about psoriasis since, although the condition has a long history of misunderstandings.

Nowadays, the increased knowledge about the pathogenesis and comorbidities of psoriasis has contributed to a new understanding of psoriasis as a systemic disease. At the same time, the identification of specific molecular targets has led to the emergence of a variety of modern treatments able to significantly reduce the severity of the disease and sometimes change its natural history.

The therapeutic management of psoriatic patients has changed profoundly over the last century, evolving from an exclusively topical approach to one more oriented towards the containment of systemic inflammation.

The advent of target treatments has radically changed the therapeutic management of psoriatic patients, and the initial doubts about the safety profile of these drugs in the long term have been definitively dispelled.

This Special Issue provides a concise overview of the long history of clinicians’ understanding of psoriasis and its treatments.

Dr. Anna Campanati
Dr. Giulia Radi
Dr. Emanuela Martina
Dr. Federico Diotallevi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriasis
  • natural history
  • biologics
  • topical treatment
  • small molecules
  • pathogenesis
  • systemic treatments

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 5003 KiB  
Article
Effects of Different Therapeutic Approaches on Redox Balance in Psoriatic Patients
by Marija V. Medovic, Vesna M. Milicic, Ana B. Ravic Nikolic, Gordana J. Ristic, Rasa H. Medovic, Marina R. Nikolic, Aleksandra Z. Stojanovic, Sergey B. Bolevich, Natalia G. Bondarchuk, Alexander A. Gorbunov, Slobodanka L. Mitrovic, Vladimir Lj. Jakovljevic and Ivan M. Srejovic
Biomedicines 2024, 12(3), 587; https://doi.org/10.3390/biomedicines12030587 - 6 Mar 2024
Viewed by 925
Abstract
Given that oxidative stress represents an important etiological factor in the pathogenesis of psoriasis, the aim of this study was to assess the effects of different therapeutic approaches, methotrexate, secukinumab, and ustekinumab on systemic oxidative stress biomarkers in psoriatic patients. This study involved [...] Read more.
Given that oxidative stress represents an important etiological factor in the pathogenesis of psoriasis, the aim of this study was to assess the effects of different therapeutic approaches, methotrexate, secukinumab, and ustekinumab on systemic oxidative stress biomarkers in psoriatic patients. This study involved 78 psoriatic patients, divided into the group treated with methotrexate (23 patients), secukinumab (28 patients), and ustekinumab (27 patients), and 15 healthy controls. Oxidative stress biomarkers (index of lipid peroxidation measured as TBARS, nitrites (NO2−), superoxide anion radical (O2−), and hydrogen peroxide (H2O2)) and antioxidative defense system (superoxide dismutase (SOD) activity, catalase (CAT) activity, and reduced glutathione (GSH)) were determined spectrophotometrically from the blood before the initiation of therapy in 16th, 28th, and 52nd week. O2− and SOD showed the most prominent changes comparing the psoriatic patients and healthy controls. CAT activity was significantly lower in psoriatic patients, and methotrexate induced a further decline in CAT activity. Ustekinumab induced a significant increase in GSH level after 52 weeks of treatment, while methotrexate reduced GSH. All applied therapeutic options induced a reduction in PASI, BSA, DLQI, and EARP. Biological drugs exert more pronounced antioxidant effects compared to methotrexate, which is most clearly observed in the values of O2− and SOD. Full article
(This article belongs to the Special Issue Psoriasis-Two Centuries after Its Discovery: Pathogenesis and Treatment)
►▼ Show Figures

Figure 1

9 pages, 760 KiB  
Article
Risk Factors of Ixekizumab-Induced Injection Site Reactions in Patients with Psoriatic Diseases: Report from a Single Medical Center
by I-Heng Chiu and Tsen-Fang Tsai
Biomedicines 2023, 11(6), 1718; https://doi.org/10.3390/biomedicines11061718 - 15 Jun 2023
Cited by 1 | Viewed by 2430
Abstract
Ixekizumab (Taltz®) is a humanized anti-IL-17A monoclonal antibody approved for the treatment of various inflammatory diseases including psoriasis and psoriatic arthritis. Despite the favorable efficacy and safety, ixekizumab is also known for its high incidence of injection site reactions (ISRs), ranging [...] Read more.
Ixekizumab (Taltz®) is a humanized anti-IL-17A monoclonal antibody approved for the treatment of various inflammatory diseases including psoriasis and psoriatic arthritis. Despite the favorable efficacy and safety, ixekizumab is also known for its high incidence of injection site reactions (ISRs), ranging from 6% to 55% in different studies according to different definitions and studied population. However, specific risk factors for ixekizumab-induced injection site reactions in patients with psoriatic diseases had not been well studied. In this retrospective study, we found that overweight or obesity might be a protective predictor for the occurrence of ixekizumab-induced ISRs in patients with psoriatic disease. Meanwhile, having a positive family history of psoriasis might be a potential risk factor. Last but not least, patients with diarrhea following ixekizumab injection were associated with a higher risk of developing ISRs. Future high-quality studies with larger samples are warranted to verify the relationship. Full article
(This article belongs to the Special Issue Psoriasis-Two Centuries after Its Discovery: Pathogenesis and Treatment)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop